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erythropoietin in chronic kidney disease a
myth?
Dear Editor,
We read with great interest the article by Yeh and col-
leagues,1 entitled “Is the renoprotective effect of erythro-
poietin in chronic kidney disease a myth?”, published in the
esteemed Journal of the Formosan Medical Association. In
this article, they discussed the evidence in favor of the
renoprotective potential of erythropoietin in patients with
chronic kidney disease. However, they suggested further
clinical studies to decide when to start erythropoietin treat-
ment and determine the optimal erythropoietin dosage for
slowing disease progression in patients with chronic kidney
disease. More importantly, they speculated that the appli-
cation of erythropoietin for kidney protection might need to
be prior to that for erythropoiesis.1 In this context, we would
like topresent a fewpoints about the kidney protective effect
of erythropoietin. In a study of 40maleWistar rats, performed
to evaluate the ameliorative effect of erythropoietin on
tubular cells, we found that erythropoietin was able to pre-
vent the increase in serum creatinine and blood urea nitrogen
levels. Furthermore, coadministration of gentamicin and
erythropoietin effectively reduced the kidney tissue damage
induced by gentamicin, compared to the control group. Our
investigation disclosed the kidney protective effect of
erythropoietin, when the drug was given in combination with
gentamicin. However, the protective properties of erythro-
poietin were evident even when the drug was applied after
induction of tubular damage by gentamicin, and it was still
effective after tissue injury.2 This indicates that erythropoi-
etin may have a curative effect, in addition to its preventive
properties.2 Thus, erythropoietin is a promising kidney pro-
tective agent that can prevent, ameliorate, or attenuate
tubular damage induced by gentamicin or other nephrotoxic
agents such as cyclosporine.3,4 Various studies have also
shown the beneficial effect of erythropoietin on renal allo-
graft survival. It seems reasonable that we start erythropoi-
etin prior to erythropoiesis, as Yeh et al1 described in theirDOI of original article: http://dx.doi.org/10.1016/
j.jfma.2013.05.005.
0929-6646/$ - see front matter Copyright ª 2013, Elsevier Taiwan LLC
http://dx.doi.org/10.1016/j.jfma.2013.05.006article; however, the curative effect of this drug should also
be considered. In this regard, to better understand the
renoprotective properties of erythropoietin, more experi-
mental or clinical studies are suggested.
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